The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20

Postma, Tjeerd J.; Aaronson, Neil K.; Heimans, Jan J.; Muller, Mirte; Hildebrand, Jerzy; Delattre, Jean‐Yves; Hoang-Xuân, Khê; Lantéri-Minet, Michel; Grant, Robin; Huddart, Robert; Moynihan, Clare; Maher, Jane; Lucey, R.

doi:10.1016/j.ejca.2005.02.012

Cited by 453 publications

(372 citation statements)

References 17 publications

Supporting

Mentioning

361

Contrasting

Unclassified

Order By: Relevance

“…Up to the present time it is true that effective intervention methods for CIPN have been insufficient [2]. Based on the results of this study, we aim to provide the basic materials of intervention development for alleviation of CIPN and QOL improvement.…”

Section: Discussionmentioning

confidence: 99%

“…The original EORTC QLQ-CIPN20, developed by Postma et al, [2] as a subscale of the European Organization for the Research and Treatment of Cancer quality of life questionnaire core 30 items (EORTC QLQ-30), was comprised of 20 questions (on a 4-point Likert scale) that assessed CIPN, and included 3 subscales to assess motor (8 items), sensory (9 items), and autonomic (3 items) symptoms, as well as function [2]. Three items from the autonomic scale ("Were you dizzy when standing up from a sitting or lying position?…”

Section: ) Chemotherapy-induced Peripheral Neuropathy (Cipn)mentioning

confidence: 99%

“…Comprised of motor, sensory, and/or autonomic neuron dysfunction and resulting in peripheral neuropathic signs [2], indolent symptoms of CIPN include numbness, loss of postural balance, muscle weakness, tingling, systemic weakness, and concentration disorders. Pain may manifest as burning, myalgia (muscle pain), stabbing, or prickling [3] and is dependent upon the type of chemotherapeutic agent used; cumulative chemotherapy agent dosages; prior chemotherapy treatments [4] the presence of diabetic mellitus, alcohol abuse, or nutrient deficiencies and patient age [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Song

Kim

Lee

2015

Korean J Adult Nurs

View full text Add to dashboard Cite

Purpose: This study was aimed to identify the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) among patients with hematologic malignancies and to examine the relationship between the quality of life (QOL) and CIPN. Methods: A total of 66 patients with CIPN-related symptoms participated in this study. Data were collected through self-reported questionnaires consisted of the European Organization for Research and Treatment of Cancer QLQ-C30 version 3.0 and the 16-item QLQ-CIPN20. Data were analyzed with SPSS/ WIN20 for descriptive statistics using the Mann-Whitney and Kruskal-Wallis tests, and Spearman's rho. Results: The mean lower and upper extremity scale scores were 31.95 and 23.16 respectively for the 16-item QLQ-CIPN20. The mean QLQ-C30 subcategory scores were 46.84 for global health status, 58.72 for functional scales, and 34.85 for symptom scales. The CIPN-related lower extremity scale symptoms correlated negatively with the QOL subscales. There was no correlation between CIPN-related upper extremity symptoms and health-related QOL. Conclusion: Patients with hematologic malignancies treated with neurotoxic chemotherapeutic agents had CIPN-related symptoms in the lower extremities mainly, and their QOL functional subscale scores were relatively lower than those of other cancer patients. Interventions need to be developed for patients with hematologic malignancies to alleviate CIPN and enhance their QOL.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: ) Chemotherapy-induced Peripheral Neuropathy (Cipn)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Song

Kim

Lee

2015

Korean J Adult Nurs

View full text Add to dashboard Cite

show abstract

“…Cavaletti et al (2003) observed that, "Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common and potentially disabling side effect of….anticancer agents…it might represent the dose-limiting side effect of the treatment, thus impairing patients' quality of life and the effectiveness of treatment." Indeed, the incidence may be as high as 100% according to Postma et al (2005), who described a questionnaire devised to elicit patients' symptoms and functional limitations related to CIPN for the European Organization for Research and Treatment of Cancer (EORTC). It is meant as a supplement to the Total Neuropathy Scale (TNS) used by neurologists (Cavaletti et al, 2007), which does not include quality of life ratings.…”

Section: Sensory Endpointsmentioning

confidence: 99%

Chemobrain: A translational challenge for neurotoxicology

Weiss

2008

NeuroToxicology

View full text Add to dashboard Cite

Neurotoxicity is a frequent accompaniment of cancer chemotherapy, and held by many oncologists to be the major dose-limiting side effect. It appears in many forms, but attracted attention during the past decade primarily because of complaints by patients of impaired cognitive function they have labeled as "chemobrain". Neuropsychological testing confirmed the validity of these complaints and has generated a substantial literature examining different aspects of cognitive impairment in various clinical populations undergoing a variety of treatments. Cognitive impairment is far from the only manifestation of neurotoxicity induced by chemotherapy, however. It alters sensory function and motor function as well. A critical need for patients is a suite of methods that will enable clinicians to trace the onset and progression of neurotoxicity so as to guide and balance decisions about the course of chemotherapy. This commentary describes some of the potential methods and encourages neurotoxicologists to enlist their unique skills in the service of these needs.

show abstract

“…As the symptoms and severity of peripheral neuropathy are largely subjective in nature, it is logical that assessments of neuropathy should be based, at least in part, on selfreported patient data. For these reasons, patient-based assessment instruments such as the Functional Assessment of Cancer Therapy/Gynecologic Oncology GroupNeurotoxicity (Fact/GOG-Ntx) (Calhoun et al, 2003), the QLQ-CIPN20 of the European Organization for Research and Treatment of Cancer (EORTC) (Postma et al, 2005), and the Patient Neurotoxicity Questionnaire (PNQ) (Hausheer et al, 2006) have been used in combination with or instead of physician-based instruments. VAS is a long-established and excellent instrument for evaluating subjective symptoms (Huskisson, 1974).…”

mentioning

confidence: 99%

The Kampo Medicine Goshajinkigan Prevents Neuropathy in Breast Cancer Patients Treated with Docetaxel

Abe¹,

Kawai²,

Mori³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Goshajinkigan (GJG) is used for the treatment of several neurological symptoms. We investigated the efficacy of GJG and mecobalamin (B12) against neurotoxicity associated with docetaxel (DOC) in breast cancer patients. Materials and Methods: Sixty breast cancer patients were treated with DOC. Thirty-three patients (GJG group) received oral administration of 7.5 g/day GJG and 27 patients (B12 group) received oral administration of 1500 μg/day B12. Neuropathy was evaluated according to DEB-NTC (Neurotoxicity Criteria of Debiopharm), Common Terminology Criteria for Adverse Events (NCI-CTC) ver. 3.0, and a visual analogue scale (VAS). This study employed a randomized open design. Results: The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01). In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases. Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases, and VAS was 2.7±2.2. In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively; and grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case, and VAS was 4.9±2.4. Conclusions: Concomitant administration of GJG is useful in preventing neuropathy in breast cancer patients treated with a DOC regimen.

show abstract

The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20

Cited by 453 publications

References 17 publications

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Chemobrain: A translational challenge for neurotoxicology

The Kampo Medicine Goshajinkigan Prevents Neuropathy in Breast Cancer Patients Treated with Docetaxel

Contact Info

Product

Resources

About